Logo image of ACTDU

ARCLIGHT CLEAN TRANSITION II (ACTDU) Stock Price, Quote, News and Overview

NASDAQ:ACTDU - Nasdaq - KYG0R21B1200 - Currency: USD

7.655  -2.59 (-25.32%)

Fundamental Rating

3

Taking everything into account, ACTDU scores 3 out of 10 in our fundamental rating. ACTDU was compared to 0 industry peers in the Unkown industry. ACTDU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ACTDU is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ACTDU had negative earnings in the past year.
ACTDU Yearly Net Income VS EBIT VS OCF VS FCFACTDU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 -5M -10M -15M

1.2 Ratios

Industry RankSector Rank
ROA -3.84%
ROE N/A
ROIC -1.57%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACTDU Yearly ROA, ROE, ROICACTDU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 -1 -2 -3 -4 -5

1.3 Margins

ACTDU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACTDU Yearly Profit, Operating, Gross MarginsACTDU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021

More info and screens

6

2. Health

2.1 Basic Checks

ACTDU has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
There is no outstanding debt for ACTDU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACTDU Yearly Shares OutstandingACTDU Yearly Shares OutstandingYearly Shares Outstanding 2021 10M 20M 30M
ACTDU Yearly Total Debt VS Total AssetsACTDU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 100M 200M 300M

2.2 Solvency

An Altman-Z score of 4.67 indicates that ACTDU is not in any danger for bankruptcy at the moment.
There is no outstanding debt for ACTDU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.67
ROIC/WACC-0.18
WACC8.71%
ACTDU Yearly LT Debt VS Equity VS FCFACTDU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 50M 100M 150M 200M 250M

2.3 Liquidity

ACTDU has a Current Ratio of 6.50. This indicates that ACTDU is financially healthy and has no problem in meeting its short term obligations.
ACTDU has a Quick Ratio of 6.50. This indicates that ACTDU is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 6.5
Quick Ratio 6.5
ACTDU Yearly Current Assets VS Current LiabilitesACTDU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 500K 1M 1.5M

More info and screens

1

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1176.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACTDU will show a very strong growth in Earnings Per Share. The EPS will grow by 87.01% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y166.47%
EPS Next 2Y110.48%
EPS Next 3Y75.51%
EPS Next 5Y87.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACTDU Yearly Revenue VS EstimatesACTDU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 1B 2B 3B
ACTDU Yearly EPS VS EstimatesACTDU Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2 4 6 8 10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ACTDU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 6.41, the valuation of ACTDU can be described as very cheap.
When comparing the Price/Forward Earnings ratio of ACTDU to the average of the S&P500 Index (20.44), we can say ACTDU is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 6.41
ACTDU Price Earnings VS Forward Price EarningsACTDU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACTDU Per share dataACTDU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ACTDU's earnings are expected to grow with 75.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y110.48%
EPS Next 3Y75.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACTDU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCLIGHT CLEAN TRANSITION II

NASDAQ:ACTDU (7/21/2022, 8:00:00 PM)

7.655

-2.59 (-25.32%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)05-16 2022-05-16/amc
Earnings (Next)N/A N/A
Inst Owners1.85%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap297.74M
Analysts85.71
Price Target20.79 (171.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.41
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)1.19
Fwd EY15.59%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS7.1
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.84%
ROE N/A
ROCE N/A
ROIC -1.57%
ROICexc N/A
ROICexgc -1.57%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.5
Quick Ratio 6.5
Altman-Z 4.67
F-Score4
WACC8.71%
ROIC/WACC-0.18
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1176.25%
EPS Next Y166.47%
EPS Next 2Y110.48%
EPS Next 3Y75.51%
EPS Next 5Y87.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A